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Abstract
Background: Blood is a convenient sample and increasingly used for quantitative gene expression measurements
with a variety of diseases including chronic fatigue syndrome (CFS). Quantitative gene expression measurements
require normalization of target genes to reference genes that are stable and independent from variables being
tested in the experiment. Because there are no genes that are useful for all situations, reference gene selection is
an essential step to any quantitative reverse transcription-PCR protocol. Many publications have described
appropriate genes for a wide variety of tissues and experimental conditions, however, reference genes that may be
suitable for the analysis of CFS, or human blood RNA derived from whole blood as well as isolated peripheral
blood mononuclear cells (PBMCs), have not been described.
Findings: Literature review and analyses of our unpublished microarray data were used to narrow down the pool
of candidate reference genes to six. We assayed whole blood RNA from Tempus tubes and cell preparation tube
(CPT)-collected PBMC RNA from 46 subjects, and used the geNorm and NormFinder algorithms to select the most
stable reference genes. Phosphoglycerate kinase 1 (PGK1) was one of the optimal normalization genes for both
whole blood and PBMC RNA, however, additional genes differed for the two sample types; Ribosomal protein large,
P0 (RPLP0) for PBMC RNA and Peptidylprolyl isomerase B (PPIB) for whole blood RNA. We also show that the use of a
single reference gene is sufficient for normalization when the most stable candidates are used.
Conclusions: We have identified PGK1 as a stable reference gene for use with whole blood RNA and RNA derived
from PBMC. When stable genes are selected it is possible to use a single gene for normalization rather than two or
three. Optimal normalization will improve the ability of results from PBMC RNA to be compared with those from
whole blood RNA and potentially allows comparison of gene expression results from blood RNA collected and
processed by different methods with the intention of biomarker discovery. Results of this study should facilitate
large-scale molecular epidemiologic studies using blood RNA as the target of quantitative gene expression
measurements.
Background
High-throughput and quantitative gene expression stu-
dies are carried out to identify biomarkers and deter-
mine the pathophysiology of many complex diseases.
Blood is often studied as a systemic sensor of multi-sys-
tem pathology, particularly in situations where anatomic
lesions are lacking or inaccessible such as chronic fati-
gue syndrome (CFS) and neuropsychiatric diseases [1-4].
Peripheral blood is a convenient specimen for molecular
epidemiologic studies and is a standard clinical sample
as it is collected with minimally invasive procedures.
Blood collection and processing methods vary. Periph-
eral blood mononuclear cells (PBMC) may be isolated
using either ficoll-hypaque purification methods or cell
preparation tubes (CPT). However, isolating PBMCs
requires sample processing within several hours of col-
lection to assure RNA integrity and preservation of
expression profile. Each of the isolations requires signifi-
cant hands-on time and up to four hours to complete,
making the equipment and personnel requirements for
closely spaced time series impractical. Isolation of
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expression profile [5,6]. To overcome these limitations,
blood collection systems that allow immediate lysis of
cells and preparation of nucleic acids without prior iso-
lation of PBMCs are now available from BD Diagnostics
(Paxgene Blood Tube) and Applied Biosystems (Tempus
Whole Blood Tube). In these methods yielding whole
blood RNA, RNA stabilization and lysis buffer is mixed
with the blood as it is drawn into the tube, minimizing
changes from the in-vivo gene expression profile. These
tubes also provide an advantage for field studies as the
lysed whole blood can be stored at room temperature or
at 4°C for 5-7 days, or it can be stored long term at -20°
C [7].
PBMCs and whole blood RNA show differences in the
cell populations that contribute. PBMC RNA is from
mostly T-, B-, natural killer cells and monocytes. Whole
blood RNA also includes neutrophils (about 70% of
white blood cells), basophils, eosinophils, granulocytes
and vast numbers of red blood cells, some of which are
immature and retain messenger RNA [8].
A critical need in quantitative gene expression studies
is the identification of reference genes (stably expressed
genes) to normalize the expression of target genes in a
particular sample [9-11]. While there are studies report-
ing the identification of reference genes for a variety of
specimens, this information is lacking for blood in the
context of different collection and processing methods.
Studies of CFS with PBMCs used reference genes
including Phosphoglycerate kinase 1 (PGK1) [12], Pepti-
dylprolyl isomerase B (PPIB) [13], and Glyceraldehyde
phosphate dehydrogenase (GAPDH) [14], while CFS stu-
dies using whole blood RNA isolated from Paxgene
tubes have used Transcription factor II B (GTF2B)[ 1 5 ] ,
GAPDH [16-18], and 18S rRNA [19]. Although many of
these studies compared multiple candidate genes, only
one study [12] reports using currently recognized algo-
rithms like geNorm [10] or NormFinder [11] to quanti-
tatively assess whether these genes are the most stably
expressed. Publications from other diseases that have
used these algorithms have identified Ribosomal protein
large, P0 (RPLP0) as a stable reference gene for ficoll-
hypaque isolated PBMC [20]; while RPLP0 [20], Tyrosine
3 monooxygenase/Tryptophan 5 monooxygenase activat-
ing protein, zeta polypeptide (YWHAZ) [10,21] and PPIB
[22,23] have been validated for use with whole blood
RNA isolated either by lysis of red blood cells or by
using the Paxgene system. Although these studies have
investigated PBMC or whole blood RNA separately, a
direct comparison of results from PBMC RNA and
whole blood RNA where both samples were drawn from
the same subjects at the same time point has not been
examined. Without this direct comparison it is difficult
to evaluate if there are common reference genes suitable
for both PBMC and whole blood RNA. We examined
reference gene selection for quantitative reverse tran-
scription PCR (qRT-PCR) using Tempus whole blood
RNA and CPT isolated PBMC RNA from the same
donors.
Results
The expression of candidate reference genes were mea-
sured for 46 subjects, (21 CFS subjects and 25 non-fati-
gued, NF, controls) using qRT-PCR. Primers and
reaction efficiencies for each gene are listed in Table 1.
T h ea v e r a g ec r o s s i n gp o i n t( C p )v a l u e s ,2 5
th and 75
th
percentile, and minimum and maximum values are
shown in Figure 1, providing an indication of the overall
stability and relative quantity for each gene. On average,
Expressed Alu Repeats (EAR) was the most highly
expressed and YWHAZ had the lowest expression in
both PBMC and whole blood RNA. In terms of the
standard deviations of the Cp values, genes RPLP0,
PGK1 and PPIB appear to be the most stably expressed
in PBMCs and PGK1, PPIB,a n dDNA-directed RNA
polymerase II polypeptide A (220 kDa), (POLR2A)f o r
whole blood RNA.
Results of geNorm and NormFinder analyses for refer-
ence genes in PBMC and whole blood RNA are shown
in Table 2, with the least stable genes at the top and the
most stable at the bottom. The most variable genes as
determined by the geNorm and NormFinder algorithms
in PBMC RNA were EAR and POLR2A while YWHAZ
and RPLP0 showed the most variable expression in
whole blood RNA. PGK1 was identified as one of the
two most stable reference genes for both PBMC and
w h o l eb l o o dR N A s ,w h e r e a st h es e c o n dg e n ed i f f e r e d ;
RPLP0 for PBMC and PPIB for whole blood. The Norm-
Finder algorithm takes into account the classification of
subjects as CFS and NF but the geNorm algorithm does
not; however both algorithms identified the same two
genes indicating these genes are the most stable inde-
pendent from disease status.
T od e t e r m i n ew h e t h e ras t a b l ye x p r e s s e ds i n g l eg e n e
is sufficient for normalization of expression studies
using blood RNA we used the measure of single control
normalization error (E), first described by Vandesompele
et al. [10] with the geNorm algorithm. E was calculated
as the ratio of the ratio of two reference genes for every
combination of two samples and shown as cumulative
percent distribution (Figure 2). The value of E can be
interpreted as the fold-error in expression (ideally 1.0)
between pairs of samples, depending on the reference
gene used. We followed the standard E calculation
method to illustrate the normalization error contributed
by the single reference gene (see data analysis section).
Based on this, for the most stable genes in PBMC RNA,
RPLP0 vs PGK1, E was low with 75% of samples being
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1.6-fold (Figure 2, red dashed line). A similar magnitude
of error was observed for stable genes PPIB vs PGK1 in
whole blood RNA (Figure 2, blue solid line). To assess
the impact of using multiple reference genes, we modi-
fied the standard E algorithm where the expression of
one gene was replaced by the geometric mean of multi-
ple reference genes (i.e., comparing PGK1 to the geo-
metric mean of PPIB and RPLP0). If the use of multiple
reference genes does not change the E value then there
is no advantage to using multiple genes instead of a
single gene. It is important to avoid comparing a single
gene (i.e., PGK1) to any combination of genes that
includes itself (i.e., PGK1 + RPLP0). Accordingly, we
compared PGK1 to the geometric mean of PPIB and
RPLP0 f o rP B M C( F i g u r e2 ,g r e yd a s h e dl i n e )o rPGK1
to the geometric mean of PPIB and EAR for whole
blood (Figure 2, black dashed line). These distributions
essentially overlap with those of the single gene compar-
isons with PBMCs or whole blood RNA, indicating little
improvement in minimizing error by including addi-
tional reference genes.
To further evaluate the use of single versus multiple
reference genes, E was calculated to compare the
expression of PGK1 in whole blood vs. PBMC of each
subject. Because this comparison was between the two
tissue types, the gene stability from a combined dataset
including both whole blood and PBMC data was re-
Figure 1.
EAR        RPLP0      PGK1     POLR2A     PPIB      YWHAZ
Figure 1 Crossing point (Cp) values for each candidate gene in
Whole Blood and PBMC RNA. Boxes show the 25
th and 75
th
percentile, with lines representing the median. The whiskers show
the minimum and maximum Cp value for each gene.
Table 1 Gene specific-primers and key PCR conditions.
Gene Symbol(GenBank #)
Name
Primer (5’-3’)* Anneal-
ing
Temp (°
C)
Ampli-
con
Size
(bp)
PCR
Efficiency
YWHAZ (NM_003406)
Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein,
zeta polypeptide
FW: TGATCCCCAATGCTTC
RV: TGTTGTGACTGATCGAC
60 127 1.81
PPIB (NM_000942)
Peptidylprolyl isomerase B
FW: CAGCAAATTCCATCGTG
RV: CCGTAGTGCTTCAGTTT
60 132 1.97
RPLP0 (NM_015741)
Ribosomal protein, large, P0
FW: CCTTCTCCTTTGGGC
RV: CCGTAGTGCTTCAGTTT
60 133 1.83
PGK1 (NM_000291)
Phosphoglycerate kinase 1
FW:
CAAGAAGTATGCTGAGGCTGTCA
RV: CAAATACCCCCACAGGACCAT
58 68 1.93
POLR2A (NM_000937) Polymerase (RNA) II (DNA directed) polypeptide A, 220
kDa
FW: ATCTCTCCTGCCATGACACC
RV: AGACCAGGCAGGGGAGTAAC
62 162 1.94
EAR
Expressed Alu Repeats
FW:
GAGGCTGAGGCAGGAGAATCG
RV: GTCGCCCAGGCTGGAGTG
62 87 1.91
CAB (X56062) Arabidopsis thaliana chlorophyll A-B binding protein FW:
CTCAGGAATGGGCAGCACTACC
RV:
CAGAATCCTACAAACGCCAACAGC
60 273 1.96
*FW, forward primer; RV, reverse primer
Table 2 Reference genes listed by increasing stability in
Tempus and PBMC RNA samples.
PBMC RNA Whole blood RNA
geNorm NormFinder geNorm NormFinder
POLR2A POLR2A YWHAZ YWHAZ
EAR EAR RPLP0 RPLP0
YWHAZ PPIB POLR2A EAR
PPIB YWHAZ EAR POLR2A
RPLP0-PGK1* PGK1 PPIB-PGK1* PGK1
RPLP0 PPIB
*With the geNorm method it is not possible to distinguish between the two
most stable genes so these are listed together on one line.
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tissues were PPIB and PGK1 while the least stable genes
were RPLP0 and YWHAZ. The distributions for these
comparisons shifted to the right where 70% of samples
had < two-fold error and 90% of samples had < three-
f o l de r r o r .T h eu s eo fas i n g l eg e n e ,PGK1,( F i g u r e2 ,
green solid line) results in lower values of E than the
geometric mean of the most stable (PGK1 and PPIB)
(Figure 2, purple dashed line) and unstable (YWHAZ
and RPLP0) (Figure 2, black solid line) gene pairs. The
trend for higher E values when additional reference
genes are included also supports the use of a single
reference gene for normalization.
Discussion
From a panel of candidate genes selected using informa-
tion from our own microarray studies and the published
literature this study identified PGK1 as one of the most
stable reference genes for both PBMC and whole blood
RNAs by geNorm and NormFinder, two widely used
algorithms based on different principles for reference
gene selection [10,11]. Additional support for the use of
PGK1 as a stably expressed reference gene is provided
by the minimal standard deviation in the Cp values (Fig-
ure 1), and the essentially overlapping E-value distribu-
tions with the single and multiple gene comparisons
(Figure 2).
The geNorm algorithm is based on pair-wise compari-
son of genes in a set of samples and selects genes with
the most stable expression ratio. One drawback to this
method is that two genes may have stable expression
ratios because they are coordinately regulated. Since we
selected candidate genes from different functional
classes, contribution of coordinate regulation in the sta-
bility index is unlikely. The NormFinder algorithm pro-
vides a direct measure of variability in expression,
within and between groups and confirms that there is
not any inter-group variability (i.e. between cases and
controls) in the expression of the candidate gene. Con-
sidering some fundamental differences between these
two algorithms, it is interesting that they identified the
same pairs of stable genes for both PBMC RNA (RPLP0
and PGK1) and whole blood RNA (PPIB and PGK1).
The widely recognized geNorm algorithm argues for
the use of multiple reference genes for normalization of
qRT-PCR through the measure of single control nor-
malization error, E[10]. This earlier report showed con-
siderable variation in single gene expression in a variety
of tissues (3 and 6.4 fold at the 75
th and 90
th percentile
respectively). In our study with PBMC and whole blood
RNA, the calculated E for our two most stable single
gene measures have much lower fold-differences where
our plots are closer to the systematic error plotted in
Vandesompele et al., with a 75
th percentile of 1.4 and
90
th percentile of 1.7. This shows quantitatively that the
basis for requiring multiple genes for normalization is
dependent on the stability of the candidate genes and in
the case where stable genes are selected, it is not neces-
s a r yt ou s em o r et h a no n eg e n ef o rd a t an o r m a l i z a t i o n .
A limitation of this analysis is the inability to compare
PGK1 to a normalization factor that includes PGK1 and
the second most stable gene within a single tissue type.
However, it is not a limitation when using the E algo-
rithm to evaluate whole blood and PBMC samples from
the same subject. The use of a single gene, PGK1 and
the two most stable genes (PGK1 and PPIB) had similar
distributions in this cross-tissues analysis further sup-
porting the use of a single gene for normalization. The
higher values of E for these comparisons across two dif-
ferent tissue types are expected and indicate that < 3-
fold differences are not likely to be meaningful when
doing this kind of cross-tissue comparison.
The most variable genes identified in Tempus whole
blood RNA include YWHAZ and RPLP0; contradicting
previous whole blood RNA studies using the Paxgene
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Figure 2 Calculated Normalization Error (E) for single and
multiple reference genes. Normalization error values (E) were
calculated as the ratio of the ratio of two reference genes in two
different samples as described in Vandesompele et. al. [10] with
modifications (see materials and methods) and are shown as
cumulative percent distribution for each sample type. The graph
shows independent measurements in Whole Blood and PBMC:
Whole Blood, PPIB vs. PGK1-blue solid line; PBMC, RPLP0 vs. PGK1-red
dashed line. These overlap with the comparisons to the calculated
geometric mean (GM) of the two most stable reference genes:
Whole Blood, PGK1 vs. GM (PPIB and EAR)-black dashed line or
PBMC, PGK1 vs. GM (RPLP0 and PPIB)-grey dashed line. For these
within-tissue comparisons, the fold error for 90% of the samples is
1.7 or less. In the cross-tissues analysis where PBMC was compared
to Whole Blood, the fold error for 90% of the samples is much
higher at 2.7. The fold-difference between PBMC vs. Whole Blood
normalized by PGK1 is shown as a solid green line, the geometric
mean of PPIB and PGK1 is a dashed purple line, and the geometric
mean of YWHAZ and RPLP0 is shown as a solid black line.
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the use of a different pool of candidate genes and our
selection of candidates previously identified as stably
expressed. The reference genes EAR and POLR2A were
the most variable genes in PBMC RNA in this study.
POLR2A was selected based on preliminary analysis of
microarrays done using Tempus whole blood RNA. We
included EAR as a potential reference standard based on
a recent report [24] that advocated the use of these
widely expressed 300 bp repeat sequences as a global
normalization method based on analysis of whole blood
RNA from Paxgene tubes. The high variability of EAR
and POLR2A in PBMC RNA may reflect differences in
cell populations, and in whole blood the high percentage
of a single cell type (neutrophils) may contribute to the
reduced variability of these genes.
Conclusion
We have identified stable reference genes for use with
whole blood RNA and RNA derived from PBMC.
When stable genes are selected it is possible to use a
single gene for normalization rather than two or three.
The identification of PGK1 as a suitable reference gene
for both PBMC and whole blood RNA, despite differ-
ences in cell composition, shows there is clearly a rela-
tionship between these two samples. Optimal
normalization will improve the ability of results from
PBMC RNA to be compared with those from whole
blood RNA and potentially allows comparison of gene
expression results from blood RNA collected and pro-
cessed by different methods with the intention of bio-
marker discovery. However, normalization will never
fully compensate for the differences in sample compo-
sition. Investigators must recognize that while both
samples originate from peripheral blood, they are actu-
ally different “tissues” because of cell fractionation that
occurs during processing. Results of this study should
facilitate large-scale molecular epidemiologic studies
using blood RNA as the target of quantitative gene
expression measurements.
Materials and methods
Subjects
The samples used in this analysis were obtained from a
population based study of CFS in Georgia, USA that
adhered to human experimental guidelines of the U.S.
Department of Health and Human Services and the Hel-
sinki Declaration. The CDC Human Subjects committee
approved the study protocol, and all subjects gave
informed consent. Our analysis included samples from
46 subjects (21 CFS and 25 NF), a subset of total enroll-
ment. CFS cases were identified based on the 1994
international research definition of CFS as operationa-
lized by standardized questionnaires including the
Multidimensional Fatigue Inventory, the SF-36
® Health
Survey, and the CDC symptom inventory [25].
Gene Selection
Candidate reference genes were selected by three sepa-
rate methods. Four genes were selected based on careful
review of the literature focused on previous analyses of
genes suitable for gene expression studies using PBMC:
YWHAZ, HUPO, PPIB, and PGK1 [12,13,20,23]. Because
we could not find published studies examining what
genes might be suitable for analysis of Tempus RNA, we
u s e dp r e l i m i n a r yd a t af r o mm i c r o a r r a ya n a l y s i so ft h e s e
samples to select POLR2A. We used Tempus RNA for
global gene expression analysis using the Human Exon
Array (Affymetrix, CA). In this population-based case-
control study, each subject has array results from blood
collected into Tempus tubes at several time points.
Results from preliminary microarray analysis were aver-
aged and the coefficient of variation (CV) calculated for
subjects grouped by either disease status or by time
point. In order to select a gene that is not differentially
expressed over the time course of the experiment or by
disease status; we selected the least variable gene that
had approximately equal CV in both. Based on this ana-
lysis POLR2A was selected as a candidate endogenous
control for Tempus RNA samples. POLR2A was the 18
th
least variable gene out of 17,629 genes when based on
t h et i m ec o u r s ea l o n e ,a n dt h e5 9 0
th least variable gene
when sorted based on disease status alone. We included
EAR based on a recent report advocating the utility of
EAR as a potential endogenous control [24] for human
blood because these repetitive 300 bp Alu sequences are
scattered throughout the human genome with appar-
ently no tissue-specificity in their expression. Table 1
shows the panel of candidate reference genes, exogenous
spike-in transcript and their PCR primers. We used
published primer sequences for EAR, PPIB,a n dPGK1
whereas we designed primers for POLR2A, RPLP0,a n d
YWHAZ genes using Primer 3 v.0.4.0 [26]. Except for
EAR, all gene-specific primers are intron-spanning.
Blood collection and RNA extraction
Blood was drawn into Tempus blood tubes (ABI-Life
Technologies, CA) (3 mL) or CPT (BD Biosciences, CA)
(8 mL), and transported to the laboratory under con-
trolled temperature conditions. CPTs were processed to
isolate PBMCs according to the manufacturer’si n s t r u c -
tions within 1.5 - 4 hours of the blood draw. PBMCs
were frozen in RPMI 1640 media supplemented with
10% (v/v) fetal calf serum, 100 IU/mL penicillin, 100 μg/
mL streptomycin, 2 mM L-glutamine and 10% (v/v)
DMSO, and stored in liquid nitrogen until use (approxi-
mately 9 months). RNA was isolated from PBMC, 5 ×
10
6 cells per sample, using Trizol following the
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were frozen at -20°C until extraction (< one month).
RNA was extracted from Tempus tube blood using the
5 PRIME Perfect Pure RNA Cultured Cell Kit (Fisher,
PA). For all samples, RNA quality and quantity were
assessed using Agilent 2100 Bioanalyzer RNA Nano
Chips (Agilent Technologies, CA) and a Nanodrop 1000
spectrophotometer (Thermo Scientific, DE). Nanodrop
concentrations were used to set up reactions.
Reverse Transcription (RT)
RNA (500 ng) was DNase I treated in a 10 μlv o l u m e
using the MessageClean
® Kit (GenHunter, TN) and
then reverse transcribed in the same tubes using 20 μl
reactions with Superscript™ III (Invitrogen, CA) and a
combination of Oligo(dT) and random hexanucleotide
primers (2.5 μM each) in the presence of 25 pg of a
plant gene spike-in chlorophyll a/b binding protein
(CAB) mRNA. (Stratagene, CA). Two microliters of the
RT reaction was removed prior to the addition of RT
enzyme to serve as no-RT control for detecting DNA
contamination. HeLa cell cDNA was synthesized to
serve as template for a standard curve in the LightCycler
reactions.
PCR
PCR (20 μl) was performed using the LightCycler 480
with the SybrGreen 480 Master Mix (Roche Applied
Sciences, IN) and contained 2 μlo f1 : 2 0d i l u t i o no f
cDNA and 0.5 μM of each primer. Thermal cycling con-
ditions were as follows: 1 cycle of 94°C for 5 minutes, 50
cycles of 94°C 15 seconds, annealing temperature (speci-
fic for each transcript in Table 1) for 15 seconds, and
72°C 15 seconds. Cp values were determined using the
Roche LightCycler software (v1.5.0 SP1) by the second-
derivative maximum method for each of the amplifica-
tions and compared to a standard curve created from
six 5-fold dilutions of HeLa cell cDNA, starting at 1.25
ng/μl. Efficiency of each reaction determined from the
standard curve is shown in Table 1. The external con-
trol plant gene CAB had an average Cp value of 19.38 ±
0.56 (CV, 2.9%). The variability of CAB measurements
was within 1.5 fold for > 90% of samples.
Data analysis
The standard curve normalized values for expression of
each of the 6 candidate genes were used in two algo-
rithms (geNorm and NormFinder) to determine the
most stable genes for both PBMC and whole blood
RNA. geNorm version 3.5, is a VBA applet that works
with Microsoft Excel [10]. Briefly, geNorm calculates a
gene stability measure (M) for each gene where M value
increases with decreasing stability of gene expression.
The gene with the least stability is removed from the
analysis and M values are recalculated until the two
most stable genes remain. A normalization factor is cal-
culated based on the geometric mean of the selected
reference genes. The NormFinder algorithm v 0.953 [11]
uses a statistical model to estimate the overall expres-
sion variation for each candidate gene. This generates a
stability value that is related to the systematic error that
would be introduced when using each candidate for
normalization.
The single control normalization error or E was ori-
ginally described by Vandesompele et al. [10]. We have
used this algorithm to compare the use of a single refer-
ence gene (PGK1) to the use of a normalization factor
consisting of the geometric mean of two reference
genes. The modified algorithm we used is as follows: for
any given m subjects (samples), gene expression levels
from real-time PCR of selected reference genes are mea-
sured (a). For every combination of two subjects, p and
q and a combination of reference genes j and k the
measurement error for j vs k or the E value is calculated
and represents the fold-expression difference between
samples p and q when normalized to j vs k.T h ee q u a -
tion is Rjkpq =a qj/aqk *apk/apj (if R <1t h e nE=R
-1,
else E = R). For example when comparing two distinct
reference genes such as PGK1 and PPIB, in samples 1
and 2, the resulting equation is R =( PGK1 in sample 1/
PPIB in sample 1) * (PPIB in sample 2/PGK1 in sample
2) (if R is less than one take the reciprocal R
-1 to equal
Eo t h e r w i s eR =E ) .T h i se q u a t i o nPGK1/PPIB * PPIB/
PGK1 should equal 1 if the measurements of PPIB and
PGK1 are constant in both samples. The same equation
is performed for all possible comparisons of samples
and the cumulative distribution of the E value or fold
error are plotted for Figure 2. We further modified this
equation so that instead of assessing two single refer-
ence genes, we could look at the E value when a nor-
malizing factor (such as the geometric mean of multiple
reference genes) is used. This was accomplished by
replacing either j or k with the geometric mean of mul-
tiple genes as calculated for that sample. The new equa-
tion then essentially measures PGK1/(geometric mean
of PPIB and RPLP0) * (geometric mean of PPIB and
RPLP0)/PGK1 and this equation would also be equal to
1 if expression of both the genes was constant. Clearly
as this equation is based on the ratio of j and k then it
is not appropriate to include the same gene as a part of
both j and k. (i.e., it is not meaningful to compare
PGK1/(geometric mean of PGK1 and PPIB)*(geometric
mean of PGK1 and PPIB)/PGK1 as it will be biased
because PGK1 is included in the numerator and
denominator). Therefore, to select the most stable two
genes to create a normalization factor for comparison
we resubmitted the standard curve normalized data to
geNorm without PGK1 and selected the two most stable
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and EAR for whole blood.
For cross-tissues comparison, E was calculated by sub-
stituting the variables j and k for PBMC or whole blood
values of expression for a reference gene or the geo-
metric mean of multiple reference genes for each sub-
ject. The resulting equation is R =( PGK1 in subject 1
PBMC/PGK1 in subject 1 whole blood) * (PGK1 in sub-
ject 2 whole blood/PGK1 in subject 2 PBMC) (if R is
l e s st h a no n et a k et h er e c i p r o c a lR
-1 to equal E other-
wise R = E). For determining the impact of multiple
reference genes in the cross tissue comparison, we com-
bined both PBMC and whole blood expression values
into a single file and then used geNorm to identify the
most stable (PGK1 and PPIB)a n dl e a s ts t a b l e( RPLP0,
YWHAZ) genes.
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